FDA confirms 5-year market exclusivity for Vyvanse
The FDA has confirmed that Vyvanse, Shire's drug for attention-deficit/hyperactivity disorder, is entitled to market exclusivity until Feb. 23, 2012. The decision prevents Actavis and other generic-drug firms from launching their versions of the product until the five-year protection period expires.
Reuters | 10/26
This story published in FDLI SmartBrief on 10/28/2009
More from SmartBrief:
Shire receives complete-response letter for Intuniv
Tuesday, July 28, 2009
FDA approves Shire's extended-release ADHD drug
Friday, September 4, 2009
Study: Biotech drugmakers need at least 12 years of market exclusivity
Monday, July 13, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|